Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Poor response to anti-anemia drug predicts higher risk of heart disease or death

Patients with diabetes, kidney disease and anemia who don't respond to treatment with an anti-anemia drug have a higher risk of cardiovascular disease or death, researchers at UT Southwestern Medical Center have found.

The results suggest that testing such patients' responsiveness to the drug and keeping blood iron levels a little low might reduce their risk, said Dr. Robert Toto, professor of internal medicine and clinical sciences and a senior author of the study, which appeared in the New England Journal of Medicine.

"These patients required higher doses and ended up having lower hemoglobin anyway," Dr. Toto said. "The results of this study might lead us in directions that can help."

The results were an unexpected finding of a study on darbepoetin alpha, which stimulates the production of red blood cells to counteract anemia. The drug, manufactured by Amgen, is sold under the name Aranesp.

The study, called the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) showed that darbepoetin alpha works no better than a placebo for improving cardiovascular and kidney outcomes, but it did lower the risk for blood transfusion and resulted in modest improvement in patient-reported outcomes among people with diabetes, kidney disease and anemia. However, people receiving darbepoetin alpha had nearly a twofold higher risk for stroke. Cancer deaths were also higher among people receiving the drug.

Darbepoetin alpha is one of a class of anti-anemia drugs that mimics erythropoietin, the body's natural hormone that stimulates production of red blood cells.

The combination of type 2 diabetes, chronic kidney disease and anemia affect about 1 million people in the U.S.

TREAT was a double-blinded experiment with a control group that received a placebo. It included 4,038 participants, all of whom had type 2 diabetes, anemia and kidney damage, although not enough to require dialysis. Of these, 1,872 received injections of the drug, and 1,889 received placebo injections.

Participants receiving darbepoetin alpha also received periodic subcutaneous injections of the drug with the aim of increasing their levels of hemoglobin – a protein in red blood cells that carries oxygen – to a level of 13 grams per deciliter. If someone in the control group dropped to a dangerous hemoglobin level below 9 g/dl, he or she received "rescue therapy" with darbepoetin until the hemoglobin level returned to a level above 9 g/dl.

In analyzing the results, the researchers divided the participants into two groups: those whose hemoglobin levels promptly increased in response to early doses of darbepoetin alpha, and those whose bodies responded less strongly, with hemoglobin level staying low.

The participants who had poor initial responses to the drug had a higher rate of death, heart attack, stroke or heart failure, the researchers found.

The study cannot show whether those people had higher risk for those outcomes because they were in poorer health to begin with, or because of some action of the drug, the researchers stated.

However, it does raise the question of whether treatment for anemia should be customized according to a patient's response to the drug, Dr. Toto said.

"Our studies suggest that we might be able to use the initial dose response to identify high-risk groups in future studies," he said.

For instance, if a person's hemoglobin level doesn't improve within one or two months of anti-anemia treatment, it may be better to stop the drug and seek alternative treatment. A state of mild anemia might pose less cardiovascular risk in such a case than continuing or escalating the dose in an attempt to reach a normal hemoglobin level, Dr. Toto said. Conversely, for patients who respond quickly to the drug, treating them until they reach the normal goal range recommended by the Food and Drug Administration appears safer, he said.

Researchers from Brigham and Women's Hospital and Harvard Medical School; Tufts Medical Center; the University of Erlangen-Nuremburg, Germany; the Faculdade de Medicina de São José do Rio Prieto, Brazil; University Medical Center, Groningen, the Netherlands; Northwestern University Feinberg School of Medicine; Health Sciences Centre, St. John's, Canada; Mario Negri Institute for Pharmacologic Research, Italy; Amgen; and the University of Glasgow also participated in the study.

The study was funded by Amgen.

Visit to learn more about UT Southwestern's heart, lung and vascular clinical services, including for cardiovascular illnesses and conditions.

This news release is available on our World Wide Web home page at

To automatically receive news releases from UT Southwestern via e-mail, subscribe at

Aline McKenzie | EurekAlert!
Further information:

More articles from Life Sciences:

nachricht Novel mechanisms of action discovered for the skin cancer medication Imiquimod
21.10.2016 | Technische Universität München

nachricht Second research flight into zero gravity
21.10.2016 | Universität Zürich

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: New 3-D wiring technique brings scalable quantum computers closer to reality

Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.

"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...

Im Focus: Scientists develop a semiconductor nanocomposite material that moves in response to light

In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.

A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...

Im Focus: Diamonds aren't forever: Sandia, Harvard team create first quantum computer bridge

By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.

"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...

Im Focus: New Products - Highlights of COMPAMED 2016

COMPAMED has become the leading international marketplace for suppliers of medical manufacturing. The trade fair, which takes place every November and is co-located to MEDICA in Dusseldorf, has been steadily growing over the past years and shows that medical technology remains a rapidly growing market.

In 2016, the joint pavilion by the IVAM Microtechnology Network, the Product Market “High-tech for Medical Devices”, will be located in Hall 8a again and will...

Im Focus: Ultra-thin ferroelectric material for next-generation electronics

'Ferroelectric' materials can switch between different states of electrical polarization in response to an external electric field. This flexibility means they show promise for many applications, for example in electronic devices and computer memory. Current ferroelectric materials are highly valued for their thermal and chemical stability and rapid electro-mechanical responses, but creating a material that is scalable down to the tiny sizes needed for technologies like silicon-based semiconductors (Si-based CMOS) has proven challenging.

Now, Hiroshi Funakubo and co-workers at the Tokyo Institute of Technology, in collaboration with researchers across Japan, have conducted experiments to...

All Focus news of the innovation-report >>>



Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

Agricultural Trade Developments and Potentials in Central Asia and the South Caucasus

14.10.2016 | Event News

World Health Summit – Day Three: A Call to Action

12.10.2016 | Event News

Latest News

Resolving the mystery of preeclampsia

21.10.2016 | Health and Medicine

Stanford researchers create new special-purpose computer that may someday save us billions

21.10.2016 | Information Technology

From ancient fossils to future cars

21.10.2016 | Materials Sciences

More VideoLinks >>>